Tran Hadrian Hoang-Vu, Thu Audrey, Twayana Anu Radha, Fuertes Axel, Gonzalez Marco, Basta Marina, Mahadevaiah Ashwini, Mehta Krutagni Adwait, Islek Damien, James Maggie, Frishman William H, Aronow Wilbert S
From the Department of Internal Medicine, Hackensack University Medical Center - Palisades Medical Center, North Bergen, NJ.
Department of Medicine, Touro College of Osteopathic Medicine, New York, NY.
Cardiol Rev. 2025 Jul 2. doi: 10.1097/CRD.0000000000000993.
Conduction system pacing (CSP), including His bundle pacing and left bundle branch area pacing, offers a promising approach to treating heart failure (HF) with conduction system disease. This review examines the evidence supporting CSP as an alternative to traditional biventricular pacing in improving outcomes for HF patients. Studies were reviewed focusing on CSP's clinical efficacy in patients with left bundle branch block (LBBB) and those who are nonresponders to cardiac resynchronization therapy. Findings suggest that CSP enhances electrical and mechanical synchronization, improving left ventricular ejection fraction, reducing QRS duration, and leading to better clinical outcomes, including decreased HF-related hospitalizations and reduced all-cause mortality. Despite these benefits, technical challenges such as lead placement and device-related complications remain. The review concludes that CSP may offer significant advantages over conventional cardiac resynchronization therapy, particularly in patients with persistent conduction delays or myocardial scar. However, larger randomized controlled trials are needed to validate the long-term efficacy and safety of CSP across diverse patient populations. Future advancements in pacing technologies and personalized treatment strategies are expected to further refine CSP's role in HF management.
传导系统起搏(CSP),包括希氏束起搏和左束支区域起搏,为治疗伴有传导系统疾病的心力衰竭(HF)提供了一种很有前景的方法。这篇综述探讨了支持CSP作为传统双心室起搏的替代方法以改善HF患者预后的证据。回顾的研究聚焦于CSP在左束支传导阻滞(LBBB)患者以及对心脏再同步治疗无反应者中的临床疗效。研究结果表明,CSP可增强电和机械同步性,提高左心室射血分数,缩短QRS时限,并带来更好的临床结局,包括减少与HF相关的住院次数和降低全因死亡率。尽管有这些益处,但仍存在诸如导线置入和与设备相关的并发症等技术挑战。该综述得出结论,CSP可能比传统心脏再同步治疗具有显著优势,尤其是在存在持续性传导延迟或心肌瘢痕的患者中。然而,需要更大规模的随机对照试验来验证CSP在不同患者群体中的长期疗效和安全性。起搏技术和个性化治疗策略的未来进展有望进一步明确CSP在HF管理中的作用。